Intellia's One-Time Gene Treatment Cuts Attacks 81% Versus Patients' Previous Preventive Drugs
An illustrative launch timetable puts first treatments and revenue three to six months after potential approval.
Intellia Therapeutics, which develops CRISPR treatments that change DNA, reported Thursday that its experimental swelling-attack treatment reduced monthly attacks 81% versus patients' previous preventive drugs. The results, presented alongside an SEC filing, strengthen the clinical case for lonvoguran ziclumeran, or lonvo-z, as Intellia prepares for a potential launch.
Fewer Attacks Without Preventive Drugs
The comparison covered 35 participants in the late-stage HAELO trial who had used long-term preventive medication. Their attack rates before enrollment came from patients' reports covering the preceding 90 days; the analysis used data through February 10, 2026.
The earlier placebo-controlled results measured a different comparison: lonvo-z reduced attacks 87% versus placebo during weeks five through 28. Among 52 lonvo-z recipients, 62% were attack-free during that period, compared with 11% of 28 placebo recipients.
Lonvo-z is designed as a single intravenous infusion for hereditary angioedema, a genetic disease that causes painful, recurring swelling that can threaten patients' lives. It aims to permanently disable the KLKB1 gene, reducing excess production of kallikrein, a protein involved in those attacks.
Across the pooled studies, all 93 patients receiving a single 50-milligram dose had stopped long-term preventive medication at their respective data cutoffs. Follow-up reached up to four years, though fewer patients had reached the later observation points.
Durability Comes With Safety Data
Infusion reactions were the most common reported side effect, affecting 51 of 93 single-dose 50-milligram recipients. Other reported events included headaches, fatigue, respiratory infections and back pain.
Serious events included a pulmonary embolism 12 months after infusion in a patient with several risk factors, including recent COVID infection, smoking and obesity. Perforated appendicitis occurred 22 months after infusion and was considered unrelated to treatment.
Patient interviews offered another view of the treatment's effects. Among 23 early- and mid-stage study participants interviewed from January through May 2026, all described their disease as well controlled after treatment, compared with 48% before it. These accounts describe patients' experiences, separate from the placebo-controlled efficacy results.
Insurance Access Sets The Revenue Clock
Intellia estimates about 7,500 U.S. adults receive treatment for hereditary angioedema. Its illustrative launch schedule places initial prescriptions within three months of potential approval, with first infusions and revenue in months three through six. Coverage decisions and treatment-center activation could take longer.
The company is preparing community and academic infusion sites, with a goal of placing most patients within 100 miles of an authorized center. Its plans include specialty-pharmacy procurement to spare sites upfront funding and reimbursement exposure.
The FDA accepted the application for priority review in September. The agency's target decision date is March 10, 2027; approval remains pending.
Launch preparation was already central to Intellia's third-quarter update, which included $7.2 million in collaboration revenue and a $127.5 million net loss. In that earlier update, the company said existing cash should support operations at least into 2028, beyond its anticipated launch.
Danny Cohn, an internist at Amsterdam University Medical Center and HAELO principal investigator, is scheduled to present durability data Saturday at the American College of Allergy, Asthma & Immunology meeting.
Sources
- 8-K Filing — Intellia Therapeutics, Inc. (NTLA) — SEC EDGAR
- Exhibit ntla-ex99_1.htm — Intellia Therapeutics, Inc. 8-K exhibit — SEC EDGAR
- Intellia Earnings: Focus Remains on Launch Readiness for Lonvo-z as Regulatory Decision Approaches | Morningstar — morningstar.com
- Intellia Therapeutics Presents Additional Positive Clinical — globenewswire.com
- 8-K filed 2026-11-05 — Intellia Therapeutics, Inc. (earlier disclosure) — SEC EDGAR
- 8-K filed 2026-09-08 — Intellia Therapeutics, Inc. (earlier disclosure) — SEC EDGAR